Ambrx Inc.’s US$200 Million Crossover Financing Round


Wilson Sonsini Goodrich & Rosati advised WuXi AppTec Co. on the deal.

Ambrx Inc., a portfolio company of WuXi AppTec Co., Ltd., announced the completion of an oversubscribed US$200 million crossover financing round.

New investors in the crossover financing round included Fidelity Management & Research Company LLC, funds and accounts managed by BlackRock, Cormorant Asset Management, HBM Healthcare Investments, Invus, Adage Capital Partners, and Suvretta Capital Management. BofA Securities acted as the sole placement agent for the offering.

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code to create Precision Biologics, this includes next generation antibody drug conjugates (ADCs), bispecifics, and targeted immuno-oncology therapies for cancer as well as novel cytokines to modulate the immune system and long acting therapeutic peptides for metabolic and cardiovascular disease, all designed to have improved pharmacologic properties and novel biological activity.

Wilson Sonsini Goodrich & Rosati acted as WuXi AppTec’s counsel in Ambrx’s crossover financing. The Wilson Sonsini team was led by partners Weiheng Chen (Picture), Jie Zhu, and Barry Taylor, and included Xuchao Dong, Dawei Liu, Eva F. Yin, Suzie Zhao, and Jingyi Yuan.

Involved fees earner: Weiheng Chen – Wilson Sonsini Goodrich & Rosati; Xuchao Dong – Wilson Sonsini Goodrich & Rosati; Dawei Liu – Wilson Sonsini Goodrich & Rosati; Barry Taylor – Wilson Sonsini Goodrich & Rosati; Eva Yin – Wilson Sonsini Goodrich & Rosati; Jingyi Yuan – Wilson Sonsini Goodrich & Rosati; Jie Zhu – Wilson Sonsini Goodrich & Rosati;

Law Firms: Wilson Sonsini Goodrich & Rosati;

Clients: WuXi AppTec Co. Ltd.;

Author: Michael Patrini